The research conducted at Cedar Clinical Research in Draper is part of the first ever phase 3 program of psilocybin therapy, and the largest of its kind
Read more at newswire.caNuminus to research COMP360 psilocybin therapy in treatment-resistant depression as part of large phase 3 study
Newswire.ca - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here